Mali, Cameroon to get cheap HIV/AIDS drugs
Mali has become the sixth African nation to sign an agreement under theAccelerating Access Initiative, giving it access to HIV/AIDS drug treatments at heavily discounted prices.
The country has signed up with Bristol-Myers Squibb, GlaxoSmithKline, Boehringer Ingelheim and Merck & Co under the AAI, which was established last spring (Marketletter May 22, 2000) by the Joint United Nations Program on HIV/AIDS (UNAIDS) and four other UN agencies with the above companies, plus Roche.
The deal cuts the cost of a month's antiretroviral drug treatment per patient from $485 to $85, but a Mali Health Ministry spokesman said that this price is still higher than the country's minimum monthly wage. The treatments will remain "inaccessible for the vast majority of those afflicted," he said, but the government plans subsidies of up to 100% for the poorest sufferers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze